872 Malignant ovarian germ cell tumours: an international multicentre study to identify new prognostic risk factors

• Published in: International journal of gynecological cancer Vol. 33; no. Suppl 3; pp. A28 - A29
• Main Authors: Suyanto, Suyanto, Bergamini, Alice, Savva, Constantinos, Kaur, Baljeet, Saso, Srdjan, Fotopoulou, Christina, Sarwar, Naveed, Lim, Adrian, Rustin, Gordon, Sharma, Anand, Hall, Marcia, Gogbashian, Andrew, Camnasio, Cristina Angela, Merrick, Sophie, Cassani, Chiara, Pignata, Sandro, Gennaro, Cormio, Ferrandina, Gabriella, Scarfone, Giovanna, Mangili, Giorgia, Seckl, Michael
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Inc 01.09.2023; Elsevier Limited
• Subjects: Chemotherapy; Medical prognosis; Ovarian cancer; Tumors
• ISSN: 1048-891X; 1525-1438
• DOI: 10.1136/ijgc-2023-ESGO.42

Introduction/BackgroundMalignant ovarian germ cell tumours (MOGCTs) are rare and aggressive malignancies mainly affecting young women. Unlike testicular GCTs, prognostic factors are poorly understood, but small series have most consistently suggested that advanced stage best predicts worse outcomes. Here, we examine a large, international patient series to identify new adverse prognostic factors.MethodologyWe evaluated 254 patients treated in Charing Cross Hospital and Mount Vernon Cancer Centre, UK and in Multi-centre Italian Trials in Ovarian Cancer (MITO) group between 1971 and 2018. Descriptive statistical, survival and Cox regression techniques were performed using STATA (StataCorp, v.16, Texas, USA).ResultsMedian age was 26 years (IQR, 20–32). There were 22.4% dysgerminomas, 18.5% immature teratomas, 33.5% yolk sac, 17.7% mixed, 1.2% embryonal, 2.4% choriocarcinoma and 4.3% unclassified. FIGO stage distribution was 31.5% (IC/M), 12.6% (II), 40.5% (III) and 15.4% (IV). First line chemotherapy consisted of BEP, POMB/ACE or other regimens for 48.0%, 42.5% and 9.5% of patients, respectively. Recurrences received high dose chemotherapy (HDCT), conventional chemotherapy ± surgery, and surgery alone in 24.4%, 65.9% and 7.3% of cases.At multivariable analysis, age ≥35 at presentation [HR 2.3, 95%CI (1.0–5.0), p=0.04], stage [HR 1.5, 95%CI (1.0–2.1), p=0.032], and non-dysgerminoma versus dysgerminoma [HR 12.7, 95%CI (1.7–94.0), p=0.013] were significantly associated with worse cancer-specific survival (CSS). Twenty-year CSS for stage IC/M, II, III, and IV were 94.8%, 82.3%, 83.2% and 84.3%, respectively. In patients relapsing or failing to achieve a complete response, HDCT showed a trend for improved 5-year CSS compared to conventional treatments [HR 0.5, 95%CI (0.2–1.5), p=0.241].ConclusionThis study demonstrated that in addition to advanced stage, age ≥35 years, and non-dysgerminoma, but not immature teratomas, are independent adverse prognostic factors for CSS. Strikingly, stage IV disease can still achieve >80% long-term survival rates. HDCT may improve outcomes for relapsing/incomplete responding patients.